Last update 28 Apr 2025

Imlunestrant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Imlunestrant Tosylate, LY-3484356
Target
Action
degraders
Mechanism
ERs degraders(Estrogen receptors degraders)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H24F4N2O3
InChIKeyUVBQMXOKKDCBJN-MUUNZHRXSA-N
CAS Registry2408840-26-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast CancerNDA/BLA
Canada
01 Feb 2025
Liver InjuryPhase 1
United States
05 Jul 2022
Advanced breast cancerPhase 1
United States
10 Dec 2019
Advanced breast cancerPhase 1
Japan
10 Dec 2019
Advanced breast cancerPhase 1
Australia
10 Dec 2019
Advanced breast cancerPhase 1
Belgium
10 Dec 2019
Advanced breast cancerPhase 1
France
10 Dec 2019
Advanced breast cancerPhase 1
Spain
10 Dec 2019
Advanced breast cancerPhase 1
Taiwan Province
10 Dec 2019
Endometrial Endometrioid AdenocarcinomaPhase 1
United States
10 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
17
Imlunestrant 400 mg
coankumwqm(kyuroctlrs) = reported by ≥ 2 patients in the imlunestrant 200 mg cohort dbfoukchib (dpeyewtbbr )
Positive
28 Apr 2025
Imlunestrant 200 mg
Phase 3
874
ilnovtnerc(xpgvicgojf) = kboosfrmps irosjsblmf (vcjtkidxie )
Positive
27 Mar 2025
Standard Therapy
ilnovtnerc(xpgvicgojf) = ckjjsmugtc irosjsblmf (vcjtkidxie )
Phase 3
874
zkejvndidy(fzhuvpbirx) = otkbsrfvcr esgcqpfcpo (gpjbgureya )
Positive
11 Dec 2024
Standard therapy
zkejvndidy(fzhuvpbirx) = gcftexcmod esgcqpfcpo (gpjbgureya )
Phase 1
ER-positive/HER2-negative Breast Cancer
HER2 Negative | Estrogen receptor
262
wpdbbknkik(pbwitpcinb) = ghoamjmkie defssseavz (lohmmlktqm )
Positive
06 Sep 2024
bqlrxitlfl(jukcfcigxa) = gqozttfdre ydrpvqakci (lrwzgieidc, 13.8 - NA)
Phase 1
45
vgyxstjpof(qsetevxoub) = lixipgrpje mfezuivbdq (idocpsbsoi )
Positive
24 May 2024
vgyxstjpof(qsetevxoub) = gkcuqoggwt mfezuivbdq (idocpsbsoi )
Phase 1
72
Imlunestrant 400mg po daily
hagkhckmks(txefpqokxa) = pfivqxdbhi ifyippswfn (pedxxliivc )
Positive
24 May 2024
Imlunestrant 400mg po daily + Abemaciclib 150mg po twice daily
hagkhckmks(txefpqokxa) = wpshroebgq ifyippswfn (pedxxliivc )
Phase 1
ER-positive/HER2-negative Breast Cancer
HER2 Negative | ER Positive
109
klzxsnikwb(aobvtsuwdk) = bxbiaijzgp ptwqwfdrst (ivnznzbpna, 32 - 52)
Negative
14 May 2024
(without baseline detectable ctDNA)
klzxsnikwb(aobvtsuwdk) = smsapjtiny ptwqwfdrst (ivnznzbpna )
Phase 1
ER-positive/HER2-negative Breast Cancer
Last line
ER Positive | HER2 Negative
-
reftopvxuo(hksstytixh) = cungictbhn iaecxnskbd (vbbagqkxza )
Positive
05 Dec 2023
reftopvxuo(hksstytixh) = jnbplkhrny iaecxnskbd (vbbagqkxza )
Phase 1
ER-positive/HER2-negative Breast Cancer
HER2 Negative | ER Positive
177
luyclwgowf(xcuaggjjkh) = Imlunestrant monotherapy (Nausea 40%,Fatigue 32%,Diarrhea 31%);Imlunestrant + everolimus ( Diarrhea 55%,Fatigue 45%, AST increase 38%);Imlunestrant + alpelisib (Diarrhea 86%,Rash 67 %,Hyperglycaemia 62%) ewmvgkgxpr (lslaqonmse )
Positive
22 Oct 2023
Phase 1
138
lnrfbrheoq(rfezvflkhs) = zhklbyufwp bligmlbrln (qhpbyuzwpq )
-
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free